Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1434958 | 0.91 | PDE4B (0.54) | PDE4BCDK2CDK9PIK3CAMTOR | |
| SCHEMBL4523706 | 0.91 | PDE4B (0.56) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL1434665 | 0.91 | PDE4B (0.52) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL1434949 | 0.90 | PDE4B (0.55) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL1434808 | 0.90 | PDE4B (0.59) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL1434708 | 0.90 | PDE4B (0.57) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL1561659 | 0.89 | PDE4B (0.50) | PDE4BPDE3BPDE7APDE3AMTOR | |
| SCHEMBL1434597 | 0.89 | PDE4B (0.54) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL1434908 | 0.89 | PDE4B (0.53) | PDE4BPDE3BPDE7APDE3ACDK2 | |
| SCHEMBL4531434 | 0.89 | PDE4B (0.55) | PDE4BPDE3BPDE7APDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940835-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| EP-1940835-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007036733-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036733-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | PDE4B, PDE3B, PDE4A | PDE4B 1/4885PDE3B 2/4885PDE7A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.